Skip to main content
Premium Trial:

Request an Annual Quote

Provista Adds $2.5M to Series A Financing

NEW YORK (GenomeWeb News) – Provista Diagnostics today said that it has sold an additional $2.5 million of Series A preferred stock, bringing the total amount raised in the round to $7.5 million.

The additional financing was open only to existing shareholders of the firm and was raised through a sale to qualified institutional and individual investors, it said. Earlier this year, the Scottsdale, Ariz.-based developer of blood-based diagnostics for oncology-related diseases raised $5 million in the Series A round.

Proceeds will go toward expansion of its laboratory capabilities, the completion of an ongoing confirmatory clinical trial of Provista's dtectDx-Breast test, formerly called BT Test, a regulatory submission for the test, followed by commercialization of it.

The test detects biomarkers from blood samples. Used in conjunction with mammography, dtect-Breast can support the early detection of breast cancer, the company said.

Funds will also be used for general corporate purposes and the development of pipeline products.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.